{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"DNA will be genotyped for SNPs and CNV markers using the Infinium Human Omni1 array (1.2 million SNP platform) from Illumina. A gene-based association analyses for thrombocytopenia or bleeding is applied with significancy (p-value). This analysis was only conducted in the T-DM1 arm.","groups":[{"description":"T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks","id":"OG000","title":"Trastuzumab Emtansine (T-DM1)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"DNA sample collected at pre-treatment. AE is reported every 3 weeks for the first 12 weeks, then every 9 weeks for the subsequent 39 weeks.","title":"Number of SNPs With Top Associations of Trastuzumab Emtansine-induced Grade 2-4 Thrombocytopenia in the T-DM1 Arm","type":"SECONDARY","unitOfMeasure":"number of SNPs"}